BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32350067)

  • 1. Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment.
    Quintana E; Schulze CJ; Myers DR; Choy TJ; Mordec K; Wildes D; Shifrin NT; Belwafa A; Koltun ES; Gill AL; Singh M; Kelsey S; Goldsmith MA; Nichols R; Smith JAM
    Cancer Res; 2020 Jul; 80(13):2889-2902. PubMed ID: 32350067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
    Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
    Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.
    Xie J; Si X; Gu S; Wang M; Shen J; Li H; Shen J; Li D; Fang Y; Liu C; Zhu J
    J Med Chem; 2017 Dec; 60(24):10205-10219. PubMed ID: 29155585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Cell-Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer.
    Chen H; Cresswell GM; Libring S; Ayers MG; Miao J; Zhang ZY; Solorio L; Ratliff TL; Wendt MK
    Cancer Res Commun; 2022 Oct; 2(10):1104-1118. PubMed ID: 36969745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SHP2-Mediated Inhibition of DNA Repair Contributes to cGAS-STING Activation and Chemotherapeutic Sensitivity in Colon Cancer.
    Wei B; Xu L; Guo W; Wang Y; Wu J; Li X; Cai X; Hu J; Wang M; Xu Q; Liu W; Gu Y
    Cancer Res; 2021 Jun; 81(12):3215-3228. PubMed ID: 33820798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
    Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
    J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.
    Wang HQ; Mulford IJ; Sharp F; Liang J; Kurtulus S; Trabucco G; Quinn DS; Longmire TA; Patel N; Patil R; Shirley MD; Chen Y; Wang H; Ruddy DA; Fabre C; Williams JA; Hammerman PS; Mataraza J; Platzer B; Halilovic E
    Cancer Res; 2021 Jun; 81(11):3079-3091. PubMed ID: 33504557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC.
    Tang KH; Li S; Khodadadi-Jamayran A; Jen J; Han H; Guidry K; Chen T; Hao Y; Fedele C; Zebala JA; Maeda DY; Christensen JG; Olson P; Athanas A; Loomis CA; Tsirigos A; Wong KK; Neel BG
    Cancer Discov; 2022 Jan; 12(1):47-61. PubMed ID: 34353854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
    Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
    J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
    Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
    Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M
    Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712
    [No Abstract]   [Full Text] [Related]  

  • 13. A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma.
    Hu Z; Wang X; Fang H; Liu Y; Chen D; Zhang Q; Liu X; Wei D; Qu C; Wang S
    Oncotarget; 2016 Feb; 7(5):5664-76. PubMed ID: 26673822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.
    Kerr DL; Haderk F; Bivona TG
    Curr Opin Chem Biol; 2021 Jun; 62():1-12. PubMed ID: 33418513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms.
    Wang Y; Mohseni M; Grauel A; Diez JE; Guan W; Liang S; Choi JE; Pu M; Chen D; Laszewski T; Schwartz S; Gu J; Mansur L; Burks T; Brodeur L; Velazquez R; Kovats S; Pant B; Buruzula G; Deng E; Chen JT; Sari-Sarraf F; Dornelas C; Varadarajan M; Yu H; Liu C; Lim J; Hao HX; Jiang X; Malamas A; LaMarche MJ; Geyer FC; McLaughlin M; Costa C; Wagner J; Ruddy D; Jayaraman P; Kirkpatrick ND; Zhang P; Iartchouk O; Aardalen K; Cremasco V; Dranoff G; Engelman JA; Silver S; Wang H; Hastings WD; Goldoni S
    Sci Rep; 2021 Jan; 11(1):1399. PubMed ID: 33446805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade.
    Akhand SS; Liu Z; Purdy SC; Abdullah A; Lin H; Cresswell GM; Ratliff TL; Wendt M
    Cancer Immunol Res; 2020 Dec; 8(12):1542-1553. PubMed ID: 33093218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity.
    Horn LA; Riskin J; Hempel HA; Fousek K; Lind H; Hamilton DH; McCampbell KK; Maeda DY; Zebala JA; Su Z; Schlom J; Palena C
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32188703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.
    LaMarche MJ; Acker M; Argintaru A; Bauer D; Boisclair J; Chan H; Chen CH; Chen YN; Chen Z; Deng Z; Dore M; Dunstan D; Fan J; Fekkes P; Firestone B; Fodor M; Garcia-Fortanet J; Fortin PD; Fridrich C; Giraldes J; Glick M; Grunenfelder D; Hao HX; Hentemann M; Ho S; Jouk A; Kang ZB; Karki R; Kato M; Keen N; Koenig R; LaBonte LR; Larrow J; Liu G; Liu S; Majumdar D; Mathieu S; Meyer MJ; Mohseni M; Ntaganda R; Palermo M; Perez L; Pu M; Ramsey T; Reilly J; Sarver P; Sellers WR; Sendzik M; Shultz MD; Slisz J; Slocum K; Smith T; Spence S; Stams T; Straub C; Tamez V; Toure BB; Towler C; Wang P; Wang H; Williams SL; Yang F; Yu B; Zhang JH; Zhu S
    J Med Chem; 2020 Nov; 63(22):13578-13594. PubMed ID: 32910655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer.
    Gu J; Han T; Ma RH; Zhu YL; Jia YN; Du JJ; Chen Y; Jiang XJ; Xie XD; Guo X
    Int J Oncol; 2014 Feb; 44(2):481-90. PubMed ID: 24297342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.